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E-mail address: ktsirulnikov@mednet.ucla.edu (K.Aminoacylase 3 (AA3) mediates deacetylation of N-acetyl aromatic amino acids and mercapturic
acids. Deacetylation of mercapturic acids of exo- and endobiotics are likely involved in their toxicity.
AA3 is predominantly expressed in kidney, and to a lesser extent in liver, brain, and blood. AA3 has
been recently reported to interact with the hepatitis C virus core protein (HCVCP) in the yeast
two-hybrid system. Here we demonstrate that AA3 directly binds to HCVCP (Kd 10 lM) that may
by implicated in HCV pathogenesis. AA3 also revealed a weak endopeptidase activity towards the
N-terminus of HCVCP.
Structured summary of protein interactions:
AA3 cleaves HCVCP by protease assay (View interaction).
AA3 cleaves AA3 by protease assay (View interaction).
AA3 binds to HCVCP by surface plasmon resonance (View Interaction: 1, 2, 3, 4, 5)
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Hepatitis C virus (HCV) affects 3% of the world population
[1]. HCV infection is associated with liver steatosis, cirrhosis,
hepatocellular carcinoma, cryoglobulinemia, insulin resistance
and diabetes 2 mellitus. The HCV core protein (HCVCP) plays an
important role in the HCV assembly. It is formed from a single
polyprotein of about 3000 amino acids by host signal peptidase
to yield p23, a 191 a.a. protein attached to the endoplasmatic
reticulum (ER) membrane that is subsequently cleaved in the
C-terminus generating a 177(179) a.a. mature soluble protein
p21 [2]. After the release from the ER membrane and trafﬁckinglf of the Federation of European Bi
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Tsirulnikov).to the cytoplasm, HCVCP associates with lipid droplets that is
an important step in the HCV maturation [2,3]. The hydrophobic
domain 2 (118–170 a.a.) is involved in the association of HCVCP
with lipids, whereas the soluble basic N-terminal domain 1
(1–117 a.a.) interacts with the viral RNA that is responsible for
the nucleocapsid formation [2]. A recent study [4] demonstrated
that of basic residues located in two clusters (cluster 1, a.a.
6–23; cluster 2, a.a. 39–62) within the N-terminal 62 amino acids
of HCVCP, only four basic amino acids residues of cluster 2
(Arg50, Lys51, Arg59, and Arg62) are essential for the production
of infectious viral particles. Nevertheless mutation of these resi-
dues did not interfere with HCVCP subcellular localization,
HCVCP–RNA interaction, or HCVCP oligomerization [4].
The N-terminal domain also interacts with a number of host
proteins including transcription factors, receptors, and protein ki-
nases [2,3,5–7]. The interaction of the N-terminal domain with
the proteasome activator PA28c in the nucleus is involved in the
degradation of HCVCP mediated by 20S proteasome [8,9].
Recently a new binding partner of HCVCP in the host cell was
indentiﬁed using the yeast two-hybrid system, namelyochemical Societies.
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brain, blood [11,12], and mediates the deacetylation of
N-acetyl L-amino acids with aromatic side chains as well as the
deacetylation of mercapturic acids (S-conjugates of N-acetyl
cysteine) derived from the glutathione (GSH) dependent
detoxiﬁcation of exo- and endobiotics [13]. The deacetylation of
N-acetylaromatic amino acids formed from protein catabolism is
a salvage mechanism given that the majority of eukaryotic
proteins is Na-terminally acetylated [14]. The AA3 mediated
deacetylation of N-acetyl-S-(1,2-dichlorovinyl)-L-cysteine, the
excretable product of the GSH-dependent detoxiﬁcation of
trichloroethylene, in renal proximal tubules [15] is responsible
for acute renal failure induced by trichloroethylene [12,13]. The
AA3 mediated deacetylation of a mercapturic acid generated
during the GSH-dependent detoxiﬁcation of a toxic aldehyde
4-hydroxynonenal is neurotoxic [16]. Inhibition of AA3 com-
pletely protects neuronal cells from 4-hydroxynonenal toxicity
[16].
AA3 is expressed in liver and blood; therefore the AA3–HCVCP
interaction may potentially play a role in the HCV pathogenesis.
Given the potential false-positive signals in the yeast two-hybrid
system, we performed this study to determine whether AA3 and
HCVCP proteins interact.2. Materials and methods
2.1. Reagents and peptide synthesis
All chemicals were purchased from Sigma–Aldrich (St. Louis,
MO, USA) except Complete protease inhibitors cocktail that was
purchased from Roche (Indianapolis, IN, USA). The following
peptides were synthesized: STLPKPQRKT (HCVCP-short) and
STLPKPQRKTKRNTIRRPQDVKFPGG (HCVCP-long) corresponding
respectively to a.a. 2–11 and a.a. 2–27 in HCVCP, SSLPGSREPL cor-
responding to a.a. 2–11 in mouse AA3, and STENVEGKSPN corre-
sponding to a.a. 2–12 in the human sodium bicarbonate
cotransporter NBCe1-A (SCL4A4). The N-terminally acetylated
(Ac) versions of all peptides were also synthesized. The N-terminal
acetylation of these proteins (after the cleavage of a methionine)
was either predicted [17] or was demonstrated experimentally
for the HCVCP expressed in insect cells [18]. The purity of all
peptides was 95.7–98.1% as was conﬁrmed by HPLC and mass-
spectrometry (MS).
2.2. Cloning, expression and puriﬁcation of mouse AA3
Mouse AA3, with high structural and sequencing homology
(with human AA3 [11,12,16], was used in this study. Mouse AA3
was expressed in Escherichia coli as an N-terminally Strep(II)-
tagged protein using the pRSET vector (Invitrogen, Carlsbad, CA,
USA). Sequences of all constructs were conﬁrmed by bi-directional
sequencing using an ABI 310 sequencer (Perkin Elmer, Foster City,
CA, USA). E. coli was grown to the optical density of 0.6, and then
1 mM isopropyl b-D-thiogalactopyranoside was added. Three hours
later, bacterial cells were precipitated by centrifugation at 6000g
for 20 min and resuspended in PBS. The procedure was repeated
twice, and the cells were disrupted in a BugBuster™ HT Protein
Extraction Reagent (Novagen, Madison, WI, USA) containing Com-
plete protease cocktail (Roche). Mouse AA3 was puriﬁed using
afﬁnity chromatography on Streptactin Sepharose (GE HealthCare,
Piscataway, NJ, USA) in the presence of Roche complete protease
inhibitor cocktail. The enzyme was eluted from a Streptactin Se-
pharose column with 3 mM desthiobiotin in 50 mM Tris–HCl, pH
7.5, 0.2 M NaCl, and desalted on a PD MiniTrap G-25 column (GE
Healthcare). Puriﬁed AA3 was >99% purity judged by SDS–PAGE.2.3. Cloning, expression and puriﬁcation of HCVCP
The HCVCP cDNA coding a.a. 1–177 was recloned from the
pcDNA 3.1 vector containing HCVCP genotype 1 provided by War-
ren Schmidt (University of Iowa) to the pRSET vector (Invitrogen,
Carlsbad, CA, USA) as a C-terminally 6His tagged protein and
expressed in E. coli. The expressed HCVCP was solubilized in 9 M
urea in the presence of Roche protease inhibitors cocktail, and
puriﬁed using metal afﬁnity chromatography on a Ni IMAC FF col-
umn (GE HealthCare). Protein was eluted with 200 mM imidazole
in 50 mM Tris–HCl, pH 7.5, 0.2 M NaCl, 0.03% dodecyl b-D-malto-
side, and desalted on PD MiniTrap G-25 column.
2.4. Aggregation of AA3 with HCVCP and electron microscopy study of
aggregates
Equal volumes of 0.1 mM solutions of mouse AA3 and HCVCP in
0.1 M Tris–HCl, pH 7.5, were mixed. The solution was absorbed on
electron microscopic grids immediately after mixing. Grids were
washed with milliQ H2O and negatively stained with 1% uranyl
acetate. Micrographs were recorded on a 4 k  4k CCD camera at
30000–200000magniﬁcation in a FEI Tecnai F20 electron micro-
scope operated at 200 kV.
2.5. Determination of the binding constants of HCVCP and peptides to
AA3
The afﬁnity of HCVCP and peptides to mouse AA3 was measured
using the surface plasmon resonance method in a Biacore T100 (GE
HealthCare). AA3 was immobilized on a CM5 Biacore chip using
matrix activation by N-hydroxysuccinimide and 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (1:1 mixture). 50 mM Na-
phosphate buffer, pH 7.5, was used as running buffer. Mouse AA3
(10 lg/ml in running buffer) was captured on ﬂow cell 2 at a
density of 300 response units at a ﬂow rate 5 ll/min. HCVCP and
peptides were injected over ﬂow cells 1 and 2 at a ﬂow rate
30 ll/min. The complex was allowed to associate and dissociate
for 150 and 420 s, respectively. The surface was regenerated with
50 ll of 1 M NaCl (for peptides) or 50 mM NaOH (for HCVCP) in
running buffer. Various concentrations of peptides (1 lM–
10 mM) and HCVCP (0.01 lM–1mM) were injected over both ﬂow
cells, and the response curve on the ﬂow cell 1 was subtracted from
the ﬂow cell 2. The data were ﬁtted by the Kinetics/Afﬁnity analy-
sis with the Biacore T100 evaluation software, version 1.1.
2.6. Analysis of the peptide cleavage catalyzed by AA3
The reaction assay contained 3 lM AA3, 1 mM peptide or
0.1 mM HCVCP in 50 mM Tris–HCl, pH 7.5, and 1 mM CoCl2. Cobal-
t(II) was added to the assay because it has been shown to signiﬁ-
cantly activate AA3 [12]. After incubation for 18 h at 37 C, an
aliquot was diluted in milliQ H2O to a ﬁnal peptide concentration
50 lM and injected (100 ll/injection) onto a reverse phase HPLC
column (polymeric resin, 150  1 mm, 5 Å, Phenomenex, Torrance,
CA, USA) equilibrated in water/formic acid (100/0.1, v/v) and
eluted (50 ll/min) with an increasing concentration of acetonitrile
(time/% acetonitrile: 0/0, 60/100). The efﬂuent from the column
was passed in series through a ﬁxed wavelength UV detector
(215 nM) and then an Ionspray™ source interfaced with a triple
quadrupole mass spectrometer (PE Sciex API III+) that was scan-
ning from m/z 300–2000 (oriﬁce 65 volts, 6 s/scan). Accession of
spectra and deconvolution of the multiply charged ion clusters into
true molecular weight spectra was performed using the instru-
ment supplied sofware (MacSpec™ version 3.3, PE Sciex). Cleavage
sites in the peptides were determined using the EXPASY FindPept
tool (http://www.expasy.org/tools/ﬁndpept.html).
Fig. 1. Electron micrographs of negatively stained mouse AA3–HCVCP aggregates. Electron micrographs of AA3 and HCVCP solutions that were used to obtain AA3–HCVCP
aggregates are shown for comparison.
Table 1
Afﬁnity of the HCV core protein and its N-terminal peptides to mouse AA3. (Ac) shows
the N-terminal acetylation. Binding was measured using the surface plasmon
resonance method in a Biacore T100 (GE HealthCare).
Peptide Kd, lM Calculated pI
HCVCP (1–177 a.a.) 10.1 ± 4.3 11.64
Short Ac-HCVCP peptide (2–11 a.a.) 7300 ± 370 10.06
Short HCVCP (2–11 a.a.) 1580 ± 200 11.17
Long Ac-HCVCP (2–27 a.a.) 170 ± 13 11.58
Long HCVCP (2–27 a.a.) 142 ± 11 12.02
Ac-AA3 peptide (2–11 a.a.) >10000 4.37
AA3 peptide (2–11 a.a.) >10000 5.72
Ac-NBCe1-A peptide (2–12 a.a.) >10000 4.25
NBCe1-A peptide (2–12 a.a.) >10000 4.53
Fig. 2. Effect of the peptide isoelectric point (pI) on the strength of binding (Kd) to
mouse AA3. Black circles: peptides. Black square: HCVCP.
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The deacetylating activity of AA3 towards the Na-acetylated
peptides was determined in an assay, which in a total volume
2 ml contained 1 mM peptide, 3 lM AA3 in 50 mM Tris–HCl, pH
7.5, with or without 0.1 mM CoCl2. The reaction was started by
adding AA3. Aliquots of 500 ll each were taken after 0, 1, 2 and
3 h incubation at 37 C, and analyzed using an Acetate detection
kit (R-Biopharm, Darmstadt, Germany) as recommended by the
manufacturer. The boiled for 2 min wt-AA3 was used in the control
experiments.
3. Results
3.1. Peptide deacetylation by AA3
AA3 did not deacetylate any of the N-terminally acetylated pep-
tides used in this study, namely Ac-HCVCP-short, Ac-HCVCP-long,
Ac-AA3 and Ac-NBCe1-A. This is in agreement with the preferential
deacetylation by AA3 of N-acetyl aromatic not aliphatic amino
acids. In addition, no corresponding deacetylated peptides were
detected in the assay using a LC–MS technique (data not shown).
3.2. Binding of HCVCP and peptides to AA3
Precipitation was observed immediately after mixing of AA3
with HCVCP in support of the direct interaction of these proteins.
Individual proteins did not demonstrate any aggregation (Fig. 1,
left). HCVCP particles of 2–3 nm are seen that probably represent
different projection of HCVCP monomers and/or dimers. In agree-
ment with a previous study [19], AA3 is mainly represented by
dimers. A heterogeneous population of round particles of different
size (20–60 nm) assembled in signiﬁcantly larger (>1500 nm)
irregular branched structures was seen under electron microscope
in the suspension formed after mixing AA3 with HCPCP (Fig. 1,
right).
To quantitate the interaction of HCVCP with AA3 we used the
surface plasmon resonance method. The Kd value for interaction
of HCVCP with AA3 was 10.1 ± 4.3 lM (Table 1). A moderately high
afﬁnity of HCVCP to AA3 suggests that they may physically interact
in the organs/tissues where they are co-expressed, for example in
the liver and blood.
To locate the HCVCP region responsible for this interaction and
given that interactions of the core protein with different protein
partners are mostly mediated by its extreme N-terminal part
[2,4], we synthesized short (STLPKPQRKT) and long (STLPKPQRK
TKRNTIRRPQDVKFPGG) HCVCP peptides corresponding to a.a.
2–11 (HCVCP-short) and 2–27 (HCVCP-long).N-acetylated HCVCP-short peptide (Ac-HCVCP-short) had the Kd
value of 7.3 mM, whereas the non-acetylated short peptide bound
to AA3 with a higher afﬁnity (Kd = 1.6 mM). Both Ac-HCVCP-long
and HCVCP-long peptides demonstrated higher afﬁnities to AA3
(170 ± 13 and 142 ± 11, respectively) than the corresponding short
peptides but lesser afﬁnities than the full-length HCVCP (Table 1).
Again N-acetylation decreased the afﬁnity of long peptide. The data
suggested that the N-terminal acetylation impaired the binding of
a peptide to AA3 likely via decreasing of the pI value of the acety-
lated peptide. Indeed the N-acetylation of HCVCP-short decreases
its predicted pI value from 11.17 to 10.06, and HCPCP-long from
12.02 to 11.58. To further conﬁrm this hypothesis, we synthesized
two peptides with the pI values below 6, namely SSLPGSREPL cor-
responding to a.a. 2–11 in mouse AA3 (calculated pI = 5.72), and
Fig. 3. LC–MS analysis of HCVCP-short (A,B), Ac-HCVCP-short (C,D), AA3-short (E,F) and Ac-AA3-short (G,H) incubated with the intact (B,D,F,H) and boiled (A,C,E,G) mouse
AA3.
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genic sodium bicarbonate cotransporter NBCe1-A (calculated
pI = 4.53). Both non-acetylated and N-acetylated peptides were
used. Again as with HCVCP peptides, acetylated peptides of AA3
and NBCe1-A were used because of the predicted acetylation of
the second residue (Ser2) after the cleavage of a methionine [17].
Both acetylated and non-acetylated AA3 and NBCe1-A peptides
demonstrated poor binding to the enzyme (Kd > 10 mM). Fig. 2
illustrates the dependence of the afﬁnity of peptides to AA3 from
their pI values. The Kd value is signiﬁcantly decreased at the pep-
tide pI > 10.
Although the Kd values for peptide–AA3 interactions were quite
similar to the Km values of AA3 substrates [12,13], and the binding
of the peptides to the active site of AA3 could not be excluded, the
presence of several exposed negatively charged areas in the mouse
AA3 atomic structure [20] suggests that multiple sites on the sur-
face of AA3 may be involved in the interaction with HCVCP.3.3. Peptide cleavage by AA3
The binding of AA3 to HCVCP peptides suggested that AA3 may
potentially deacetylate them although the substrate speciﬁcity of
AA3, which deacetylates N-acetyl aromatic amino acids and mer-
capturic acids (N-acetyl-S-conjugates of L-cysteine) with bulky side
chains [13], did not support this suggestion. In agreement with the
substrate speciﬁcity, AA3 did not generate acetate during even
24 h incubation with N-acetylated HCVCP and other peptides.
Instead, a peptide hydrolysis was detected using LC/MS (Fig. 3A–
D). Three peptides (STLPKP, STLPKPQ and STLPKPQR) were de-
tected after incubation of both N-acetylated and non-acetylated
short HCVCP peptide (STLPKPQRKT). No C-terminal peptides were
detected. The results suggested that AA3 has endopeptidase activ-
ity towards the HCVCP peptides. This is in agreement with the
structural similarity of the active site of AA3 and carboxypeptidase
A [20]. Surprisingly, both Ac-HCVCP-long and HCVCP-long were
Fig. 3. (continued)
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than HCVCP-short to AA3, the larger size of HCVCP-long may
prevent its productive orientation towards the enzyme peptidase
site. Both the N-acetylated and non-acetylated AA3 peptide
(SSLPGSREPL) were hydrolyzed between Gly5 and Ser6 and both
moieties (SSLPG and SREPL) were present (Fig. 3E–H). Both
acetylated and non-acetylated NBCe1-A peptides were not hydro-
lyzed (data not shown). The endopeptidase activity of AA3 was
Co2+-dependent; it was not detected without this metal ion. The
endopeptidase activity of AA3 was likely attributed to the enzyme
active center since the inactive H21A mutant of AA3 did not hydro-
lyze the peptides (data not shown). The endopeptidase activity of
AA3 was not due to protease contaminants since standard protease
substrates insulin B chain and casein were not hydrolyzed (data
not shown). The Co2+-dependent endopeptidase activity of AA3
was inhibited by 50% in the presence of 1 mg/ml Pefabloc SC
suggesting that a serine residue(s) may be involved in mediating
this activity. It should be mentioned that a serine residue is notpresent in the hypothetical active site of mouse AA3 [20] although
20 serine residues are present in AA3 monomer [11,12].
4. Discussion
Our study for the ﬁrst time demonstrates that HCVCP directly
interacts with AA3. This interaction is mediated by the highly basic
extreme N-terminus of HCVCP. The interaction between AA3 and
HCVCP may play an important role in HCV pathogenesis. Binding
of AA3 to the HCV capsid may form a speciﬁc shield protecting
the virus from the recognition by the host immune system. From
this standpoint it is important to determine whether AA3 is
present on the surface of the HCV particles in vivo.
Our study provides the ﬁrst evidence for the presence of endo-
peptidase activity in a mammalian aminoacylase. Dipeptidase and
carboxypeptidase activity of several microbial aminoacylases have
been reported [21–24]. Cleavage of the neighbor amino acids in the
C-terminus of HCVCP-short suggests that AA3 also possesses
3804 K. Tsirulnikov et al. / FEBS Letters 586 (2012) 3799–3804carboxypeptidase activity. This is in a good agreement with the
similarity of the crystal structure and catalytic mechanism of
AA3 and carboxypeptidase A [20]. AA3 does not demonstrate pref-
erences for amino acids in the position P1 and P10 of the substrate
since the enzyme cleaves the peptide bonds between both charged
and uncharged amino acids. The cleavage occurs only in the C-ter-
minal and central part of peptides not in their N-terminus. The net
charge of the N-terminal part of peptides seems to be important for
their cleavage by AA3 with the preference to a positive charge. The
N-terminus of the best hydrolyzed peptide, HCVCP, has a positive
charge, the N-terminus of a signiﬁcantly less hydrolyzed AA3 pep-
tide is near neutral, while the non-hydrolyzed NBCe1-A peptide
has a negative charge in the N-terminal half. The absence of the
hydrolytic activity of AA3 towards the higher afﬁnity HCVCP-long
peptide and whole HCVCP argues for the existence of additional
binding site(s) distinct from the enzyme active site. In agreement
with this hypothesis, if the hydrolysis occurs, the dissociation of
products should be signiﬁcantly decelerated. According to the
N-end rule, the N-terminal amino acids with a bulky or charged
side chain are considered to be destabilizing and target proteins
to the site of intracellular ubiquitin-dependent proteolysis [25].
The ubiquitin-mediated degradation of the HCVCP was demon-
strated previously [9,26,27]. Cleavage of the N-terminus of HCVCP
mediated by AA3 may expose destabilizing amino acids and affect
the turnover rate of HCVCP in the cell.
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